secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001213900-21-056469
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial appoints former Indivior CFO Cary Claiborne to board of directors
-----------------------------------------------------------------------

- Cary J. Claiborne appointed to Adial's board, expanding board to seven members.
- He previously served as CFO and board member of Indivior PLC, a specialty pharma company.
- Received an option for 60,000 shares at $3.15, vesting monthly over 36 months.
- CEO Stilley noted his experience will aid preparations for Phase 3 trial completion and potential commercial launch.
- Claiborne's background includes CFO roles at Sucampo Pharmaceuticals and Osiris Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/0001213900-21-056469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/ea149870-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-056469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer